Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis

被引：0
|
作者：
Reich, K. [1 ,2 ]
Blauvelt, A. [3 ]
Armstrong, A. [4 ]
Fox, T. [5 ]
Huang, J. [5 ]
Lloyd, P. [5 ]
Bruin, G. [5 ]
机构：
[1] Dermatologikum Hamburg, Hamburg, Germany
[2] Univ Gottingen, Hamburg, Germany
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Univ Colorado, Denver Sch Med, Aurora, CO USA
[5] Novartis Pharma AG, Basel, Switzerland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2014年 / 171卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P103
引用
收藏
页码：E166 / E167
页数：2
相关论文
共 50 条
  • [31] Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial (vol 382, pg 1705, 2013)
    Baeten, D.
    Baraliakos, X.
    Braun, J.
    LANCET, 2014, 383 (9928): : 1548 - 1548
  • [32] A highly sensitive and drug-tolerant immunogenicity screening assay for ixekizumab, an anti-interleukin-17A antibody, using an affinity capture elution approach
    Muram, T.
    Sloan, J.
    Chain, J.
    Komocsar, W.
    Meiklejohn, B.
    Blauvelt, A.
    Papp, K.
    Gordon, K.
    Heffernan, M.
    Konrad, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E159 - E160
  • [33] Improvement of nail lesions in a patient with psoriatic arthritis by switching the treatment from an anti-interleukin-17A antibody to an anti-tumor necrosis factor-α antibody
    Komatsu-Fujii, Takayoshi
    Honda, Tetsuya
    Otsuka, Atsushi
    Kabashima, Kenji
    JOURNAL OF DERMATOLOGY, 2019, 46 (05): : E158 - E160
  • [34] Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis
    Roccuzzo, Gabriele
    Repetto, Federica
    Giordano, Silvia
    Sarda, Cristina
    Comes, Arianna
    Dapavo, Paolo
    Quaglino, Pietro
    Ribero, Simone
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (07)
  • [35] Immunogenicity of tumour necrosis factor inhibitors in patients with psoriasis receiving long-term treatment
    Meyer, M. W.
    Zachariae, C.
    Bendtzen, K.
    Skov, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E17 - E17
  • [36] Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition
    Napolitano, M.
    Megna, M.
    Fabbrocini, G.
    Nistico, S. P.
    Balato, N.
    Dastoli, S.
    Patruno, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) : 604 - 606
  • [37] A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
    Gordon, Kenneth B.
    Leonardi, Craig L.
    Lebwohl, Mark
    Blauvelt, Andrew
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Heffernan, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (06) : 1176 - 1182
  • [38] Autoimmune phenomena during long-term anti-TNF treatment for psoriasis: effect on the psoriasis area and severity index
    Schopf, R. E.
    Sapyega, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 55 - 55
  • [39] Secukinumab has low Immunogenicity in Patients with moderate to severe Plaque Psoriasis during a 3-Year Treatment Period
    Reich, K.
    Blauvelt, A.
    Armstrong, A. W.
    Warren, R. B.
    Messina, I
    Ren, M.
    Liang, E.
    Spindeldreher, S.
    Fox, T.
    Papavassilis, C.
    Bruin, G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 137 - 137
  • [40] Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis
    Krueger, James G.
    Pariser, David
    Tyring, Stephen K.
    Bagel, Jerry
    Alexis, Andrew F.
    Soung, Jennifer
    Armstrong, April W.
    Muscianisi, Elisa
    Kianifard, Farid
    Sarkar, Rajendra Prasad
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB37 - AB37
12345